Leaders in Law endorses Alan Zhou as our exclusively recommended Healthcare Law expert in China. If you wish to get in touch with Alan please use the contact information provided above.
Alan Zhou’s practice is focused in the areas of mergers & acquisitions, private equity/venture capital, regulatory compliance, and general corporate. Mr. Zhou has a particularly strong background in pharmaceutical and healthcare, and TMT industrial sectors.
Mr. Zhou has represented many multinational corporations, reputable Chinese state owned and private corporations, and private equity/venture capital funds. He has routinely represented such multinational corporations as Sanofi, Schlumberger, Siemens, Boehringer Ingelheim, Novartis, Aon, Bureau Veritas, Catalent, Terumo, Tosoh, Barclays, Societe Generale Bank, Samsung and SK Telecom. Mr. Zhou has not only worked for reputable Chinese private companies such as Focus Media, VIPShop, Acorn International, Hisoar Pharmaceutical, Tianyuan Biopharm, and GeneScience Pharma, he has also advised PRC state owned companies such as Shanghai Dasheng, Shanghai Industrial and Shanghai Airport Authority. In the area of PE/VC, Mr. Zhou has acted for CBRE Investors, Colony Capital, Navis Capital, Lightspeed Ventures, Qiming Ventures, DT Capital, NEA, New Alliance Capital, Warden International, WINS and other international and local PE/VC funds.
Mr. Zhou has been seconded as general counsel for China operations of Boehringer Ingelheim, a leading multinational pharmaceutical company, for more than nine years, and is responsible for various legal matters including general corporate, acquisitions and joint venture formation, compliance and regulatory, intellectual property and corporate restructuring.
Healthcare Law Practice:
Our Pharmaceutical and Healthcare (P&H) practice group is one of the leading advisers in China as this group not only has premium knowledge but also thorough understanding of the practice of P&H industry. We have provided ‘one-stop’ legal services for every area of the P&H industry, including drug R&D, clinical research organizations (CRO), pharmaceuticals, life sciences, biotechnology, medical devices, supply producers and distributors, hospitals and other healthcare providers, as well as various investment funds in the P&H sector.
Global advises clients on challenging P&H legal issues such as regulatory compliance, structuring transactions and contractual arrangements, realization of pipeline and geographic expansions, capital raising and project financing, mergers and acquisitions, reorganisations, IP protection, licensing and distribution arrangements, settlement of disputes involving adverse effects in clinical trials and medical treatment, etc.
Global also has close links to industrial associations and is involved in making recommendations on industry codes of conduct.
Global Law Office:
The history of Global Law Office dates back to 1984, when it became the first law firm in the People’s Republic of China (the “PRC”) to take an international perspective on its business, fully embracing the outside world.
In today’s global economy, we continue to set the pace as the PRC’s most innovative and progressive law firm. In doing so, we build on the energy and creativity of our highly qualified professionals, most of whom have gained qualifications and hands-on experience in law schools and firms throughout Asia, North America, Europe and Australia.
Our clients are the most important part of our business. We have attracted clients from all parts of the world, working in countless industries and market areas.
Our value is delivered to our international and domestic clients through our deep knowledge and experience across the full range of practice areas and industries affected by Chinese law. As one of the country’s most well-established and respected firms, we can bring our clients the legal and cultural understanding needed for long-term success in the PRC.